Your browser doesn't support javascript.
loading
Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone.
Albayati, Zaineb A F; Sunkara, Manjula; Schmidt-Malan, Suzannah M; Karau, Melissa J; Morris, Andrew J; Steckelberg, James M; Patel, Robin; Breen, Philip J; Smeltzer, Mark S; Taylor, K Grant; Merten, Kevyn E; Pierce, William M; Crooks, Peter A.
Afiliação
  • Albayati ZA; College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Sunkara M; Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, USA.
  • Schmidt-Malan SM; Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester, Minnesota, USA.
  • Karau MJ; Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester, Minnesota, USA.
  • Morris AJ; Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, USA.
  • Steckelberg JM; Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Patel R; Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester, Minnesota, USA Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Breen PJ; College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Smeltzer MS; Department of Microbiology and Immunology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Taylor KG; Department of Chemistry, University of Louisville, Louisville, Kentucky, USA.
  • Merten KE; Pradama, Inc., Louisville, Kentucky, USA.
  • Pierce WM; Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, USA wmpier01@louisville.edu pacrooks@uams.edu.
  • Crooks PA; College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA wmpier01@louisville.edu pacrooks@uams.edu.
Antimicrob Agents Chemother ; 60(3): 1865-8, 2015 Dec 14.
Article em En | MEDLINE | ID: mdl-26666918
ABSTRACT
We examined the pharmacokinetic properties of vancomycin conjugated to a bone-targeting agent (BT) with high affinity for hydroxyapatite after systemic intravenous administration. The results confirm enhanced persistence of BT-vancomycin in plasma and enhanced accumulation in bone relative to vancomycin. This suggests that BT-vancomycin may be a potential carrier for the systemic targeted delivery of vancomycin in the treatment of bone infections, potentially reducing the reliance on surgical debridement to achieve the desired therapeutic outcome.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteomielite / Portadores de Fármacos / Vancomicina / Durapatita / Antibacterianos Limite: Animals / Humans Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Osteomielite / Portadores de Fármacos / Vancomicina / Durapatita / Antibacterianos Limite: Animals / Humans Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos